Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Ella R, et al. Among authors: sarangi v. Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21. Lancet Infect Dis. 2021. PMID: 33485468 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai S, Panda S, Abraham P, Gupta N, Ella K, Bhargava B, Vadrevu KM. Ella R, et al. Among authors: sarangi v. Lancet Infect Dis. 2021 Jul;21(7):950-961. doi: 10.1016/S1473-3099(21)00070-0. Epub 2021 Mar 8. Lancet Infect Dis. 2021. PMID: 33705727 Free PMC article. Clinical Trial.
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, Verma S, Singh C, Redkar S, Mohapatra S, Pandey A, Ranganadin P, Gumashta R, Multani M, Mohammad S, Bhatt P, Kumari L, Sapkal G, Gupta N, Abraham P, Panda S, Prasad S, Bhargava B, Ella K, Vadrevu KM; COVAXIN Study Group. Ella R, et al. Among authors: sarangi v. Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11. Lancet. 2021. PMID: 34774196 Free PMC article. Clinical Trial.
Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
Vadrevu KM, Raju D, Rani S, Reddy S, Sarangi V, Ella R, Javvaji B, Mahantshetty NS, Battu S, Levine MM. Vadrevu KM, et al. Among authors: sarangi v. Vaccine. 2021 Oct 29;39(45):6682-6690. doi: 10.1016/j.vaccine.2021.07.073. Epub 2021 Oct 5. Vaccine. 2021. PMID: 34625288 Free article.
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments.
Krull JE, Wenzl K, Hopper MA, Manske MK, Sarangi V, Maurer MJ, Larson MC, Mondello P, Yang Z, Novak JP, Serres M, Whitaker KR, Villasboas Bisneto JC, Habermann TM, Witzig TE, Link BK, Rimsza LM, King RL, Ansell SM, Cerhan JR, Novak AJ. Krull JE, et al. Among authors: sarangi v. Cell Rep Med. 2024 Mar 19;5(3):101443. doi: 10.1016/j.xcrm.2024.101443. Epub 2024 Feb 29. Cell Rep Med. 2024. PMID: 38428430 Free PMC article.
Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes.
Antwi SO, Heckman M, White L, Yan I, Sarangi V, Lauer KP, Reddy J, Ahmed F, Veliginti S, Mejías Febres ED, Hatia RI, Chang P, Izquierdo-Sanchez L, Boix L, Rojas A, Banales JM, Reig M, Stål P, Gómez MR, Singal AG, Li D, Hassan MM, Roberts LR, Patel T. Antwi SO, et al. Among authors: sarangi v. Hum Mol Genet. 2023 Aug 7;32(16):2646-2655. doi: 10.1093/hmg/ddad099. Hum Mol Genet. 2023. PMID: 37369012
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL.
Wenzl K, Stokes M, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ. Wenzl K, et al. Among authors: sarangi v. medRxiv [Preprint]. 2023 Jun 10:2023.06.07.23290748. doi: 10.1101/2023.06.07.23290748. medRxiv. 2023. PMID: 37333387 Free PMC article. Preprint.
Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas.
Hopper MA, Wenzl K, Hartert KT, Krull JE, Dropik AR, Novak JP, Manske MK, Serres MR, Sarangi V, Larson MC, Maurer MJ, Yang ZZ, Paludo J, McPhail ED, Habermann TM, Link BK, Rimsza LM, Ansell SM, Cerhan JR, Jevremovic D, Novak AJ. Hopper MA, et al. Among authors: sarangi v. Hematol Oncol. 2023 Oct;41(4):644-654. doi: 10.1002/hon.3187. Epub 2023 May 30. Hematol Oncol. 2023. PMID: 37254453
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.
Mondello P, Paludo J, Novak JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Dasari S, Manske MK, Abeykoon JA, Sarangi V, Kapoor P, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan AA, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Mondello P, et al. Among authors: sarangi v. Clin Cancer Res. 2023 Mar 1;29(5):957-970. doi: 10.1158/1078-0432.CCR-22-2215. Clin Cancer Res. 2023. PMID: 36534518
40 results